Commodore Capital’s Soleno Therapeutics SLNO Stock Holding History

Commodore Capital’s Portfolio SLNO Stock Details SLNO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-652,432	Closed	-$21.8M	–	40
2026 Q1	$21.8M	Sell	652,432 -547,568	-46%	-$21.5M	1.26%	23
2025 Q4	$55.6M	Sell	1,200,000 -150,000	-11%	-$8.22M	3.7%	12
2025 Q3	$91.3M	Buy	1,350,000 +740,000	+121%	+$54.9M	4.46%	8
2025 Q2	$51.1M	Sell	610,000 -540,000	-47%	-$40.4M	3.61%	12
2025 Q1	$82.2M	Sell	1,150,000 -375,000	-25%	-$18.3M	6.05%	4
2024 Q4	$68.5M	Buy	1,525,000 +265,000	+21%	+$13.7M	5.02%	7
2024 Q3	$63.6M	Sell	1,260,000 -165,000	-12%	-$7.9M	3.98%	9
2024 Q2	$58.1M	Buy	1,425,000 +1,255,467	+741%	+$53.2M	3.97%	8
2024 Q1	$7.26M	Sell	169,533 -530,467	-76%	-$24M	0.49%	34
2023 Q4	$28.2M	Sell	700,000 -187,500	-21%	-$5.33M	2.46%	15
2023 Q3	$26.2M	Buy	+887,500	New	+$5.37M	3.06%	14

Commodore Capital's SLNO Position: Q2 2026 in Review

Commodore Capital sold out of Soleno Therapeutics (SLNO) in Q2 2026, closing a stake of 652,432 shares — an estimated $21.8M sold.

Commodore Capital first reported a position in SLNO in Q3 2023 and held it in 11 quarters. The position peaked at $91.3M in Q3 2025. 0 funds tracked by Wall St. Rank hold SLNO as of Q2 2026.

Commodore Capital reported no remaining Soleno Therapeutics position as of Q2 2026 after selling out during the quarter.
Commodore Capital sold 652,432 Soleno Therapeutics shares in Q2 2026, an estimated $21.8M.
Commodore Capital first reported a position in Soleno Therapeutics in Q3 2023 and held it in 11 quarters.
Commodore Capital's Soleno Therapeutics position peaked at $91.3M in Q3 2025.
0 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q2 2026.

Based on Commodore Capital's 13F filing for Q2 2026, filed 14 Aug 2026.